In conclusion, bone metastatic NSCLC patients with EGFR mutated disease, treated with modern EGFR inhibitors, have a relatively long survival expectancy and are at high risk to develop skeletal related events. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.